SG11201901449XA - Method for treating pruritus and/or itch - Google Patents

Method for treating pruritus and/or itch

Info

Publication number
SG11201901449XA
SG11201901449XA SG11201901449XA SG11201901449XA SG11201901449XA SG 11201901449X A SG11201901449X A SG 11201901449XA SG 11201901449X A SG11201901449X A SG 11201901449XA SG 11201901449X A SG11201901449X A SG 11201901449XA SG 11201901449X A SG11201901449X A SG 11201901449XA
Authority
SG
Singapore
Prior art keywords
international
pct
itch
treating pruritus
english
Prior art date
Application number
SG11201901449XA
Inventor
Moshe Laudon
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of SG11201901449XA publication Critical patent/SG11201901449XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

WO 18/037 295 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 March 2018 (01.03.2018) W I PO I PCT Hu omits I io o X0 1111 001 EMO #011 (10) International Publication Number WO 2018/037295 Al (51) International Patent Classification: A61K 31/351 (2006.01) A61P 17/04 (2006.01) A61K 31/4045 (2006.01) (21) International Application Number: PCT/IB2017/053989 (22) International Filing Date: 30 June 2017 (30.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/378,435 23 August 2016 (23.08.2016) US (71) Applicant: NEURIM PHARMACEUTICALS (1991) LTD. [IL/IL]; 27 HaBarzel Street, 6971039 Tel Aviv (IL). (72) Inventor: LAUDON, Moshe; 30th Herzel Street, 4444435 Kfar Saba (IL). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: METHOD FOR TREATING PRURITUS AND/OR ITCH (57) : The invention relates to a medicament for treating pruritus and itch in a patient suffering from dermatological and non- dermatological conditions leading to such symptoms, which comprises at least one compound selected from a pyrone-indole derivative, in an effective amount, and optionally one or more other therapeutically active agents.
SG11201901449XA 2016-08-23 2017-06-30 Method for treating pruritus and/or itch SG11201901449XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662378435P 2016-08-23 2016-08-23
PCT/IB2017/053989 WO2018037295A1 (en) 2016-08-23 2017-06-30 Method for treating pruritus and/or itch

Publications (1)

Publication Number Publication Date
SG11201901449XA true SG11201901449XA (en) 2019-03-28

Family

ID=59416750

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901449XA SG11201901449XA (en) 2016-08-23 2017-06-30 Method for treating pruritus and/or itch

Country Status (11)

Country Link
US (1) US20190175554A1 (en)
EP (1) EP3503884B1 (en)
JP (1) JP6910424B2 (en)
KR (1) KR20190040298A (en)
CN (1) CN109843286A (en)
AU (1) AU2017315265C1 (en)
CA (1) CA3033534A1 (en)
MX (1) MX2019002149A (en)
SG (1) SG11201901449XA (en)
TW (1) TW201808269A (en)
WO (1) WO2018037295A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7048051B2 (en) * 2018-07-11 2022-04-05 正徳 染井 Atopic dermatitis remedy to reduce itching
WO2021151059A1 (en) * 2020-01-24 2021-07-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Compounds and methods for treating or reducing pruritus
WO2023078252A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
WO1997000075A1 (en) * 1995-06-14 1997-01-03 Institute Of Immunology Co., Ltd. Ameliorant for pruritus cutaneous accompanying renal failure
ES2151464T3 (en) * 1996-02-07 2002-12-16 Lead Chem Co Ltd PREPARATION FOR EXTERNAL APPLICATION THAT INCLUDES TRANILAST AND PROCEDURE TO PRODUCE IT.
CA2222471A1 (en) * 1996-03-27 1997-10-02 Toray Industries, Inc. Ketone derivatives and medical application thereof
JP2000327570A (en) * 1999-05-24 2000-11-28 Nof Corp Skin preparation for external use
US6552073B1 (en) * 2002-03-01 2003-04-22 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases
US7635710B2 (en) 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
US9101613B2 (en) * 2006-02-15 2015-08-11 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
JP5513705B2 (en) * 2006-03-29 2014-06-04 小林製薬株式会社 Hypersensitivity skin itching agent
WO2008036979A2 (en) * 2006-09-22 2008-03-27 Guilford F Timothy Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes
KR101359078B1 (en) * 2011-03-08 2014-02-05 이홍식 Method of processing roots of wild ginseng
RU2015143834A (en) * 2013-03-15 2017-04-24 Дженентек, Инк. SUBSTITUTED BENZOXAZOLE AND METHODS OF USE
CN105492430B (en) * 2013-03-15 2017-10-10 基因泰克公司 Substituted benzoxazole and its application method

Also Published As

Publication number Publication date
US20190175554A1 (en) 2019-06-13
AU2017315265B2 (en) 2021-03-11
JP2019524797A (en) 2019-09-05
TW201808269A (en) 2018-03-16
CN109843286A (en) 2019-06-04
AU2017315265A1 (en) 2019-02-28
AU2017315265C1 (en) 2021-06-10
CA3033534A1 (en) 2018-03-01
EP3503884B1 (en) 2021-07-21
EP3503884A1 (en) 2019-07-03
MX2019002149A (en) 2019-09-18
JP6910424B2 (en) 2021-07-28
KR20190040298A (en) 2019-04-17
WO2018037295A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
SG11201808990QA (en) Compositions for topical application of compounds
SG11201900799XA (en) Pyridopyrimdinone cdk2/4/6 inhibitors
SG11201908391XA (en) Methods for modulating an immune response
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201909949XA (en) Targeted immunotolerance
SG11201907034PA (en) Methods of treating influenza
SG11201908420WA (en) Compositions of plinabulin and use thereof
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201407200TA (en) Liquid formulation
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201903786UA (en) Farnesyltransferase inhibitors for use in methods of treating cancer
SG11201900486WA (en) Treatment and prevention of sleep disorders
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201810801QA (en) Brain delivery protein
SG11201910206QA (en) Methods and compositions for treating inflammatory gastrointestinal disorders
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201907217RA (en) Pharmaceutical combinations for treating cancer